Myo-inositol supplementation reduces the amount of gonadotropins and length of ovarian stimulation in women undergoing IVF: a systematic review and meta-analysis of randomized controlled trials
- 229 Downloads
To evaluate whether oral myo-inositol supplementation (MI) is able to reduce the amount of gonadotropins (GA) and the length of controlled ovarian hyperstimulation (SL) in both Polycystic Ovarian Syndrome (PCOS) and non-PCOS women undergoing in vitro fertilization (IVF).
We performed a systematic review (PROSPERO ID: CRD42017069439) of randomized controlled trials (RCTs). We searched articles published in English between January 1985 to August 2017, using the combination of the Medical Subject Headings “Inositol” with “Ovulation Induction”, “follicle-stimulating hormone, human, with HCG C-terminal peptide”, “Reproductive Techniques, Assisted”, and “Fertilization in Vitro”. We collected data about GA and SL comparing MI to no treatment or d-Chiro-Inositol (DCI) supplementation (controls). A subgroup analysis was performed to evaluate selected outcomes in PCOS and non-PCOS women.
We included 8 studies embedding 812 participants. We found a reduction in GA (p < 0.00001) and SL (p = 0.0007) in patients receiving MI with respect to controls. MI was effective in both PCOS (p < 0.00001) and non-PCOS women (p = 0.02) in reducing GA; conversely, MI supplementation decreased the SL only in PCOS women (p < 0.00001).
During IVF, MI is effective in both PCOS and non-PCOS women in saving gonadotropins, but reduces efficiently SL only in PCOS women.
KeywordsMyo-inositol In vitro fertilization Recombinant follicle-stimulating hormone Controlled ovarian hyperstimulation
ASL: designed the systematic review and lead its development. AV and MN: performed the meta-analysis of retrieved data. GA: edited the manuscript. RD: supervised the development of the systematic review and meta-analysis and gave the final approval. All the authors concurred to screen the literature, include relevant data and write the manuscript. All the authors fulfil the International Committee of Medical Journal Editors (ICMJE) criteria.
The work was not supported by any grant/fund.
Compliance with ethical standards
Conflict of interest
The authors have no proprietary, financial, professional, or other personal interest of any nature in any product, service, or company. The authors alone are responsible for the content and writing of the paper.
This article does not contain any studies with human participants or animals performed by any of the authors.
For this type of study, formal consent is not required.
- 6.Noventa M, Vitagliano A, Quaranta M, Borgato S, Abdulrahim B, Gizzo S (2016) Preventive and therapeutic role of dietary inositol supplementation in periconceptional period and during pregnancy: a summary of evidences and future applications. Reprod Sci 23:278–288. https://doi.org/10.1177/1933719115594018 CrossRefPubMedGoogle Scholar
- 7.Paul C, Laganà AS, Maniglio P, Triolo O, Brady DM (2016) Inositol’s and other nutraceuticals’ synergistic actions counteract insulin resistance in polycystic ovarian syndrome and metabolic syndrome: state-of-the-art and future perspectives. Gynecol Endocrinol 32:431–438. https://doi.org/10.3109/09513590.2016 CrossRefPubMedGoogle Scholar
- 8.Vitagliano A, Noventa M, Gizzo S (2015) Is it time to consider patients suffering from endometriosis-related infertility as “novel candidates” for targeted peri-conceptional d-chiro inositol supplementation? Hypothesis, rationale and some considerations. J Assist Reprod Genet 32:407–408. https://doi.org/10.1007/s10815-014-0412-z CrossRefPubMedGoogle Scholar
- 10.Papaleo E, Unfer V, Baillargeon JP, Fusi F, Occhi F, De Santis L (2009) Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Fertil Steril 91:1750–1754. https://doi.org/10.1016/j.fertnstert.2008.01.088 CrossRefPubMedGoogle Scholar
- 11.Colazingari S, Treglia M, Najjar R, Bevilacqua A (2013) The combined therapy myo-inositol plus d-chiro-inositol, rather than d-chiro-inositol, is able to improve IVF outcomes: results from a randomized controlled trial. Arch Gynecol Obstet 288:1405–1411. https://doi.org/10.1007/s00404-013-2855-3 CrossRefPubMedGoogle Scholar
- 12.Pacchiarotti A, Carlomagno G, Antonini G, Pacchiarotti A (2016) Effect of myo-inositol and melatonin versus myo-inositol, in a randomized controlled trial, for improving in vitro fertilization of patients with polycystic ovarian syndrome. Gynecol Endocrinol 32:69–73. https://doi.org/10.3109/09513590.2015.1101444 CrossRefPubMedGoogle Scholar
- 13.Mendoza N, Pérez L, Simoncini T, Genazzani A (2017) Inositol supplementation in women with polycystic ovary syndrome undergoing intracytoplasmic sperm injection: a systematic review and meta-analysis of randomized controlled trials. Reprod Biomed Online 35:529–535. https://doi.org/10.1016/j.rbmo.2017.07.005 CrossRefPubMedGoogle Scholar
- 15.Higgins JPT, Green S (eds) (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available from http://handbook.cochrane.org
- 16.Rizzo P, Raffone E, Benedetto V (2010) Effect of the treatment with myo-inositol plus folic acid plus melatonin in comparison with a treatment with myo-inositol plus folic acid on oocyte quality and pregnancy outcome in IVF cycles. A prospective, clinical trial. Eur Rev Med Pharmacol 14:555–561Google Scholar
- 20.Lisi F, Carfagna P, Oliva MM, Rago R, Lisi R, Poverini R, Manna C, Vaquero E, Caserta D, Raparelli V, Marci R, Moscarini M (2012) Pretreatment with myo-inositol in non polycystic ovary syndrome patients undergoing multiple follicular stimulation for IVF: a pilot study. Reprod Biol Endocrinol 10:52. https://doi.org/10.1186/1477-7827-10-52 CrossRefPubMedPubMedCentralGoogle Scholar
- 21.Schillaci R, Mangione D, Lo Monte G, Vassiliadis A (2012) Inositol supplementation and IVF outcome: preliminary data. Ital J Gynaecol Obstet 21:38–44Google Scholar
- 22.Artini PG, Di Berardino OM, Papini F, Genazzani AD, Simi G, Ruggiero M, Cela V (2013) Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study. Gynecol Endocrinol 29:375–379. https://doi.org/10.3109/09513590.2012.743020 CrossRefPubMedGoogle Scholar
- 24.Lesoine B, Regidor PA (2016) Prospective randomized study on the influence of myoinositol in PCOS women undergoing IVF in the improvement of oocyte quality, fertilization rate, and embryo quality. Int J Endocrinol 2016:4378507. https://doi.org/10.1155/2016/4378507 CrossRefPubMedPubMedCentralGoogle Scholar
- 25.The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81:19–25Google Scholar
- 29.Busnelli A, Papaleo E, Del Prato D, La Vecchia I, Iachini E, Paffoni A, Candiani M, Somigliana E (2015) A retrospective evaluation of prognosis and cost-effectiveness of IVF in poor responders according to the Bologna criteria. Hum Reprod 30:315–322. https://doi.org/10.1093/humrep/deu319 CrossRefPubMedGoogle Scholar
- 31.Csokmay JM, Yauger BJ, Henne MB, Armstrong AY, Queenan JT, Segars JH (2010) Cost analysis model of outpatient management of ovarian hyperstimulation syndrome with paracentesis: “Tap early and often” versus hospitalization. Fertil Steril 93:167–173. https://doi.org/10.1016/j.fertnstert.2008.09.054 CrossRefPubMedGoogle Scholar